← Back to headlines
Acadia Pharmaceuticals Upgraded on Improved Risk-Reward Profile
Acadia Pharmaceuticals has received an upgrade, with analysts citing an improved risk-reward profile for the company following a recent pullback in its stock.
25 Mar, 18:51 — 25 Mar, 18:51
Sources
Showing 1 of 1 sources
